FDA Confirms GLP-1 RA Safety Review: No Increas...

By HEOR Staff Writer

February 2, 2026

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysi...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Navigating Economic Resilience Through Life Sciences Investment
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Novartis Drug Pricing Agreement
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...